Pila Pharma AB is a clinical-stage biotechnology company based in Malmö, Sweden, established in 2014. The company focuses on developing oral treatments that target the TRPV1 receptor, primarily for conditions such as type 2 diabetes and erythromelalgia. In March 2021, Pila Pharma completed a pre-IPO funding round, raising 15 million SEK to fund ongoing clinical studies and prepare for a public listing, which received conditional approval for trading on Nasdaq First North Growth Market Stockholm in June 2021. As of July 2026, Pila Pharma's stock was trading at 1.275 SEK, with an approximate market capitalization of 85.88 million SEK. In 2025, the company reported revenues of 1.13 million SEK, reflecting a 42.65% increase from the previous year. The company is led by CEO Gustav Hanghoj Gram and founder Dorte Xenia Gram, who serves as Chairman and Chief Scientific Officer. Pila Pharma's scientific advisory board includes experts such as Bo Ahrén, Arpad Szallasi, Mark Evans, and Jens Juul Holst. One of its main products, XEN-D0501, is a TRPV1 antagonist currently in clinical trials for multiple indications, including obesity, diabetes, heart failure, erythromelalgia, inflammation pain, and rare diseases.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
PILA PHARMA AB's offering is currently approved on OTHER. PILA PHARMA AB is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with PILA PHARMA AB.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/pila-pharma-ab" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="PILA PHARMA AB — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/pila-pharma-ab?theme=light as the src instead.
https://www.discoveripo.com/ipo/pila-pharma-ab/opengraph-image
PILA PHARMA AB IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/pila-pharma-ab?utm_source=embed&utm_medium=text&utm_campaign=pila-pharma-ab
Get emailed when PILA PHARMA AB's terms, price, or expected date change — no weekly noise, just this company.
PILA PHARMA AB is listing on OTHER.
Pila Pharma AB is a clinical-stage biotechnology company based in Malmö, Sweden, established in 2014. The company focuses on developing oral treatments that target the TRPV1 receptor, primarily for conditions such as type 2 diabetes and erythromelalgia. In March 2021, Pila Pharma completed a pre-IPO funding round, raising 15 million SEK to fund ongoing clinical studies and prepare for a public listing, which received conditional approval for trading on Nasdaq First North Growth Market Stockholm in June 2021. As of July 2026, Pila Pharma's stock was trading at 1.275 SEK, with an approximate market capitalization of 85.88 million SEK. In 2025, the company reported revenues of 1.13 million SEK, reflecting a 42.65% increase from the previous year. The company is led by CEO Gustav Hanghoj Gram and founder Dorte Xenia Gram, who serves as Chairman and Chief Scientific Officer. Pila Pharma's scientific advisory board includes experts such as Bo Ahrén, Arpad Szallasi, Mark Evans, and Jens Juul Holst. One of its main products, XEN-D0501, is a TRPV1 antagonist currently in clinical trials for multiple indications, including obesity, diabetes, heart failure, erythromelalgia, inflammation pain, and rare diseases.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy